Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

Likui Fang, Luming Wang, Yiqing Wang, Wang Lv and Jian Hu

Abstract

Background: Surgery is an important part of multidisciplinary treatment strategy for locally advanced lung squamous cell carcinoma (LSCC), but insufficient evidence supports the feasibility and safety of video assisted thoracic surgery (VATS) following neoadjuvant chemotherapy for locally advanced LSCC. This study aims to compare perioperative data and long-term survival of locally advanced LSCC patients between VATS and thoracotomy after neoadjuvant chemotherapy.

Methods: We retrospectively collected the clinical and pathological information of patients with locally advanced LSCC who underwent surgical resection after neoadjuvant chemotherapy from October 2013 to October 2017. All patients were divided into two groups (thoracotomy and VATS) and were compared the differences in perioperative, oncological and survival outcomes.

Results: A total of 81 patients were analyzed in this study (67 thoracotomy and 14 VATS). VATS provided less postoperative pain (\(P = 0.005\)) and produced less volume of chest drainage (\(P = 0.019\)) than thoracotomy, but the number of resected lymph nodes was less in VATS group (\(P = 0.011\)). However, there was no significant difference in the number of resected lymph node stations and the rate of nodal upstaging between two groups. The mean disease free survival (DFS) was 32.7 ± 2.7 months for the thoracotomy group and 31.8 ± 3.0 months for the VATS group (\(P = 0.335\)); the corresponding overall survival (OS) was 41.7 ± 2.2 months and 36.4 ± 4.1 months (\(P = 0.925\)).

Conclusion: In selected patients with locally advanced LSCC, VATS played a positive role in postoperative recovery and associated similar survival outcome compared with thoracotomy after neoadjuvant chemotherapy.

Keywords: Locally advanced lung squamous cell carcinoma, Neoadjuvant chemotherapy, Video assisted thoracic surgery, Thoracotomy

Introduction

Lung cancer is one of the most common cancers and the leading cause of cancer-related death in the world, and more than 80% of patients have a group of histological subtypes known as non-small cell lung cancer (NSCLC) [1]. Lung adenocarcinoma (LA) and lung squamous cell carcinoma (LSCC) are the most common subtypes of NSCLC [2]. Although operable early stage NSCLC has satisfactory prognosis with the improvement of medical technology [3, 4], the 5-year survival rate of locally advanced NSCLC (LANSCLC) with surgery alone is only 20–35% [5]. So far, the treatment of LANSCLC has evolved from surgery alone to multidisciplinary pattern. It has been proven that neoadjuvant chemotherapy could significantly improve overall survival, time to distant recurrence, and recurrence-free survival [6], while preoperative radiotherapy do not add any survival benefit to neoadjuvant chemotherapy followed by surgery [7]. Neoadjuvant chemotherapy has been a valid treatment option for most of patients with LANSCLC. However, there also have been many controversial debates about...
the operation based multidisciplinary treatment, one of which is the selection of surgical approaches after neoadjuvant chemotherapy, thoracotomy or video assisted thoracic surgery (VATS).

VATS is superior to open surgery for the resection of early stage NSCLC, because it can minimize complications, provide less pain and offer faster recovery with at least equivalent long-term survival rate [8, 9]. VATS was initially proposed only for operable early stage lung cancer, but in recent years it has been carried out by some experienced thoracic surgeons in LANSCLC with satisfactory outcome [10, 11]. However, there were only few studies reporting the outcome of VATS following neoadjuvant therapy [12, 13] and currently, no published study reported the comparison between VATS and thoracotomy following neoadjuvant chemotherapy in locally advanced LSCC staged by the eighth American Joint Committee on Cancer (AJCC 8) staging system.

In this study, we aimed to compare perioperative data and long-term survival of locally advanced LSCC patients between VATS and thoracotomy after neoadjuvant chemotherapy. The primary goal of this study was to explore the feasibility and safety of VATS following neoadjuvant chemotherapy for locally advanced LSCC in terms of intraoperative and postoperative outcomes.

**Methods**

**Patients selection**

The study protocol was approved by the Institutional Review Board of the First Affiliated Hospital of Zhejiang University, School of Medicine. The data in this study was collected retrospectively from hospital electronic medical records system, including demographic characteristics, preoperative investigations, intraoperative data and postoperative course between October 2013 and October 2017.

All patients included in the analysis were restaged by AJCC 8 staging system [14] and fitted the following criteria: (1) the disease was pathologically diagnosed as LSCC; (2) the patient did not have distant metastasis before neoadjuvant chemotherapy; (3) the surgery was preceded by neoadjuvant chemotherapy.

We excluded patients with a history of previous cancers, other concurrent malignant disease and patients who underwent pulmonary resection previously. Locally advanced squamous lung cancer was mainly defined as stageII, while the patients with stage T3 was also regarded as locally advanced disease. Clinical lymph node (LN) status was assessed by CT scan, PET scan and/or endobronchial ultrasound. Tumor size was defined as the maximum diameter of the pathological specimens.

Patients were retrospectively classified into the thoracotomy group and VATS group on the basis of the surgical approach. Patients undergoing conversion in the VATS group were eliminated from the study group.

**Treatment protocol and response assessment**

Neoadjuvant chemotherapy consisted of platinum-based two-drug regimen with 2 cycles, while the cycle was adjusted with tumor response and adverse effects after systematic evaluation. Generally, the resection was performed within 6 weeks after neoadjuvant chemotherapy and adjuvant therapy was carried out depending on the recovery condition of patients. Tumor response was classified according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria [15]. The patients who had received at least 1 cycle of chemotherapy were candidates for response assessment.

**Surgical procedures**

All patients underwent general anesthesia with single-lung ventilation and were placed in lateral decubitus position. Conventional posterolateral serratus divided thoracotomies were performed in the open procedures, and 3-ports approach was adopted in the thoracoscopic procedures. Generally, bronchi, pulmonary vasculature and parenchyma were resected by the corresponding endoscopic cut stapler. Prior closing, the cavity was rinsed by normal saline to detect potential air leak and one chest tube was placed in the appropriate position at the end of the procedure. The tube was removed when it was clearly confirmed no air leak and the volume of drainage was less than 200 mL/day. In contrast, when pneumonectomy was performed the tube was normally clipped after surgery and removed when there was no abnormal appearance in roentgenograms.

**Follow-up**

Follow-up data were collected by telephone calls and reviewing the records of reexamination in the outpatient clinic. The last follow-up time was February 2018. The outcomes of interest of the current study included disease-free survival (DFS) and overall survival (OS). DFS was calculated from the day of surgery to the date of cancer recurrence or death from any cause. Patients who did not have a recurrence or who did not die during the study period were censored at the date they were last confirmed to be alive with no evidence of disease. OS was calculated from the day of surgery to the time of death. Patients who did not die during the study period were censored at the date they were last confirmed to be alive.

**Statistical analysis**

The measurement data and numeration data were statistically analyzed with t test and $\chi^2$ test respectively. DFS and OS were estimated using the Kaplan-Meier method.
All the above analysis was conducted by SPSS software (version 19.0, IBM SPSS Inc. United States). The statistical power analysis was further conducted by R (version 3.2.5; R Development Core Team) when the differences between the two groups were statistical significant. Statistical significance was set at \( P \) value < 0.05 (All \( P \) values presented were 2-sided).

**Result**

**Patients' characteristics**

From October 2013 to October 2017, a total of 83 patients fitted the criteria for inclusion in the study: 67 treated with thoracotomy and 16 treated with VATS. Two patients converted to thoracotomy because of severe adhesions were eliminated from the VATS group, so there were 67 patients in the thoracotomy group and 14 patients in the VATS group finally. The major demographic and clinical characteristics were listed in Table 1. There was no significant gender difference between thoracotomy group and VATS group, in which the male gender occupied 94.0 and 78.6%, respectively. The age was also similar between two groups. It was comparable in the two groups for the number of patients with other possible prognostic factors which might be predictive of survival, including body mass index (BMI) [16], weight loss (more than 5%) [17] and other nutritional status [18].

**Disease characteristics**

The disease characteristics of two groups were listed in Table 2 in detail. There was no significant difference between thoracotomy group and VATS group in the clinical stage before neoadjuvant chemotherapy with 54 (80.6%) and 13 (92.9%) patients in stage IIIA or IIIB, respectively. It was worth mentioning that 14 patients (13 in thoracotomy group and 1 in VATS group) with IIIA disease in seventh AJCC staging system were restaged as IIB disease in eighth AJCC staging system. More than half of the patients received the regimens consisted of gemcitabine and platinum with 2 cycles in both groups. T stage was similar in two groups either before neoadjuvant chemotherapy of after, as well as the number of T downstaging. Clinical complete response (cCR) was seen in 1 patient in both groups, retrospectively, while 43 (64.2%) patients in thoracotomy group and 11 (78.6%) patients in VATS group were evaluated as partial response (PR). Only 4 (6.0%) patients in thoracotomy group were classified in progressive disease (PD), with one patient having oligometastasis in 11th thoracic vertebra. However, the primary tumor of the patient with oligometastasis was detected with only few cancer cells under the microscope. The number of patients with downstaging after neoadjuvant chemotherapy which was a certain prognostic factor was comparable in two groups. There was also no statistical difference in pathologic stage and tumor size between two groups.

**Table 1** The demographic and clinical characteristics in the thoracotomy and VATS group

| Variables                  | Thoracotomy (N = 67) | VATS (N = 14) | \( P \) value |
|----------------------------|----------------------|--------------|---------------|
| Male gender                | 63 (94.0%)           | 11 (78.6%)   | 0.177         |
| Age (year)                 | 60 (29–77)           | 61 (55–73)   | 0.182         |
| Smoking                    | 59 (88.1%)           | 11 (78.6%)   | 0.608         |
| Drinking                   | 29 (43.3%)           | 5 (35.7%)    | 0.602         |
| BMI                        | 23 (17–30)           | 23 (18–29)   | 1             |
| Weight loss                | 15 (22.4%)           | 2 (14.3%)    | 0.752         |
| Hypertension               | 12 (17.9%)           | 6 (42.9%)    | 0.091         |
| Diabetes                   | 5 (7.5%)             | 1 (7.1%)     | 1             |
| COPD                       | 1 (1.5%)             | 0 (0)        | 1             |
| Lymphocyte (10^9/L)        | 1.5 (0.8–4.0)        | 1.6 (0.7–3.2) | 0.954         |
| Total protein (g/L)        | 68.8 (54.4–82.4)     | 67.3 (39.2–80.6) | 0.077         |
| Albumin (g/L)              | 41.6 (26.6–54.8)     | 39.2 (20.9–50.9) | 0.128         |
| Serum Creatinine (mmol/L)  | 69.0 (52.0–105.0)    | 68.5 (50.0–119.0) | 0.507         |
| Serum trioxypurine (mmol/L)| 296.5 (192.0–455.0)  | 319.5 (157.0–462.0) | 0.676         |
| Triglyceride (mmol/L)      | 1.1 (0.4–4.1)        | 1.2 (0.7–3.0) | 0.581         |
| Cholesterol (mmol/L)       | 4.2 (2.7–6.1)        | 4.3 (2.7–8.0) | 0.399         |

Values are N (percentage) or median (range)

BMI body mass index, COPD chronic obstructive pulmonary disease, VATS video assisted thoracic surgery
Table 2 The disease characteristics in the thoracotomy and VATS group

| Variables                          | Thoracotomy (N = 67) | VATS (N = 14) | P value |
|------------------------------------|----------------------|---------------|---------|
| T stage before neoadjuvant chemotherapy |                      |               | 0.135   |
| 0                                 | 0 (0)                | 1 (7.1%)      |         |
| 1b                                | 1 (1.5%)             | 2 (14.3%)     |         |
| 1c                                | 25 (37.3%)           | 3 (21.4%)     |         |
| 2a                                | 7 (10.4%)            | 2 (14.3%)     |         |
| 3                                 | 19 (28.4%)           | 3 (21.4%)     |         |
| 4                                 | 15 (22.4%)           | 3 (21.4%)     |         |
| Clinical stage before neoadjuvant chemotherapy |                    |               | 0.508   |
| IIB                               | 13 (19.4%)           | 1 (7.1%)      |         |
| IIIA                              | 32 (47.8%)           | 7 (50.0%)     |         |
| IIIB                              | 22 (32.8%)           | 6 (42.9%)     |         |
| Neoadjuvant chemotherapy regimen  |                      |               | 0.664   |
| Docetaxel + platinum              | 16 (23.9%)           | 2 (14.3%)     |         |
| Paclitaxel + platinum             | 16 (23.9%)           | 3 (21.4%)     |         |
| Gemcitabine + platinum            | 35 (52.2%)           | 9 (64.3%)     |         |
| Cycles of neoadjuvant chemotherapy | 2 (1 – 5)            | 2 (2 – 4)     | 0.930   |
| T stage after neoadjuvant chemotherapy |                    |               | 0.058   |
| 0                                 | 1 (1.5%)             | 1 (7.1%)      |         |
| 1b                                | 1 (1.5%)             | 2 (14.3%)     |         |
| 1c                                | 0 (0)                | 1 (7.1%)      |         |
| 2a                                | 42 (62.7%)           | 8 (57.1%)     |         |
| 2b                                | 6 (9.0%)             | 0 (0)         |         |
| 3                                 | 14 (20.9%)           | 1 (7.1%)      |         |
| 4                                 | 3 (4.5%)             | 1 (7.1%)      |         |
| Clinical stage after neoadjuvant chemotherapy |                |               | 0.308   |
| 0                                 | 1 (1.5%)             | 1 (7.1%)      |         |
| IB                                | 15 (22.4%)           | 4 (28.6%)     |         |
| IIA                               | 1 (1.5%)             | 0 (0)         |         |
| IIIB                              | 12 (17.9%)           | 0 (0)         |         |
| IIIA                              | 25 (37.3%)           | 7 (50.0%)     |         |
| IIIB                              | 12 (17.9%)           | 2 (14.3%)     |         |
| VI                                | 1 (1.5%)             | 0 (0)         |         |
| Response assessment               |                      |               | 0.261   |
| cCR                               | 1 (1.5%)             | 1 (7.1%)      |         |
| PR                                | 43 (64.2%)           | 11 (78.6%)    |         |
| SD                                | 19 (28.4%)           | 2 (14.3%)     |         |
| PD                                | 4 (6.0%)             | 0 (0)         |         |
| T downstaging                     | 28 (41.8%)           | 9 (64.3%)     | 0.124   |
| TNM downstaging                   | 29 (43.3%)           | 8 (57.1%)     | 0.344   |
| Pathologic stage                  |                      |               | 0.221   |
| IA                                | 1 (1.5%)             | 3 (21.4%)     |         |
| IB                                | 22 (32.8%)           | 3 (21.4%)     |         |
| IIA                               | 2 (3.0%)             | 0 (0)         |         |
| IIIB                              | 18 (26.9%)           | 3 (21.4%)     |         |
Table 2 The disease characteristics in the thoracotomy and VATS group (Continued)

| Variables | Thoracotomy (N = 67) | VATS (N = 14) | P value |
|-----------|----------------------|--------------|---------|
| IIIA      | 18 (26.9%)           | 4 (28.6%)    |         |
| IIIB      | 5 (7.5%)             | 1 (7.1%)     |         |
| VI        | 1 (1.5%)             | 0 (0)        |         |
| Tumor size (cm)* | 3.1 (0.8–8.0) | 2.5 (1.0–7.0) | 0.335   |

Values are N (percentage) or median (range)

*cCR clinical complete response, PR partial response, SD stable disease, PD progressive disease*

*Only few cancer cells in 4 patients were observed microscopically (3 patients in thoracotomy group and 1 in VATS group), so the tumor size of the 4 cases was unable to measure*

Perioperative data

The detailed information of surgical outcome was presented in Table 3. Surgical procedure was comparable in both groups, although there was no double sleeve lobectomy and pneumonectomy in VATS group. In contrast, the number of resected lymph nodes in thoracotomy group was more than that in VATS group (P = 0.011, power = 80.4%), but there was no significant difference in the number of resected lymph node stations and the case of nodal upstaging. The rate of negative surgical margin in VATS group reached up to 92.9% which seemed to be higher than that in thoracotomy group but the difference was not of statistically significance. The operation time and blood loss were also similar in two groups, but the volume of chest drainage in VATS group was less than that in thoracotomy group (P = 0.019, power = 80.1%), although the duration of chest drainage was comparable. In addition, the VATS group had a clear advantage over the thoracotomy group in terms of postoperative pain (P = 0.005, power = 62.2%) which was recorded by numerical rating scale (NRS) [19]. Perioperative complications ranked by Clavien-Dindo classification [20] were comparable in thoracotomy and VATS groups with 9 (13.4%), 9 (13.4%), 2 (3.0%) and 1 (7.1%), 2 (14.3%), 0 (0) in Gradel, GradeII, GradeII, respectively. The length of postoperative hospital stay was also comparable in two groups. The delay and protocol of adjuvant therapy after surgery in thoracotomy group were similar to those in VATS group as well.

Survival outcome

Follow-up information was successfully collected from 73 of 81 patients with median follow-up time of 15 months (range: 3 to 48 months). Tumor recurrence and death occurred in 18 cases (9 deaths, 9 alive with disease). Four patients evaluated as PD after neoadjuvant chemotherapy were all alive during the follow-up period. The patient who had oligometastasis in 11th thoracic vertebra received concurrent chemoradiotherapy and had been living for more than 3 months after surgery with satisfactory life quality. Other patients had been living for 9, 13 and 16 months after surgery, respectively, with one patient alive with disease. The mean DFS and OS were 32.7 ± 2.7 months, 41.7 ± 2.2 months for the thoracotomy group and 31.8 ± 3.0 months, 36.4 ± 4.1 months for the VATS group, respectively. The differences between two groups were not statistically significant (Figs. 1 and 2).

Discussion

In spite of the increased prevalence of early stage NSCLC with satisfactory survival outcome, the treatment of LANSCLC remains challenging. Early stage NSCLC patients are commonly treated with radical resection, but unfortunately most patients with LANSCLC do not benefit clearly by surgery alone or even by chemoradiotherapy [21]. In the result, neoadjuvant therapy has been proposed in order to better achieve local and distant disease control in LANSCLC. Although neoadjuvant chemoradiotherapy followed by surgery had been proven to be a feasible and safe treatment strategy [22, 23], several subsequent studies reported that preoperative radiotherapy significantly increased the occurrence of bronchopleural fistula after surgery [24] and did not add any survival benefit to neoadjuvant chemotherapy followed by surgery [7, 25]. Of course, neoadjuvant chemotherapy had some controversial problems, one of which was the challenges in surgery, including perioperative complications, interval time and the surgical approach.

In spite of lacking multicenter prospective researches, a large number of retrospective studies proved that neoadjuvant chemotherapy did not add any extra risk to the occurrence of perioperative complications and mortality [7, 26, 27] even though mediastinal structures become differently affected after neoadjuvant chemotherapy. In addition, the optimal interval time from the end of neoadjuvant chemotherapy to surgery was proven to be not more than 6 weeks [28]. However, there was little evidence suggesting the preferable surgical approach after neoadjuvant chemotherapy in LANSCLC, especially in local advanced LSCC, thoracotomy or VATS. Historically, VATS was initially recommended only for early stage disease, but with the technological improvement and growing experience, a few experts started to use the VATS platform to carry out pulmonary resection in...
LANSCLC. Jun Huang et al. [13] publishing a single institution retrospective series of 43 cases reported that VATS following neoadjuvant therapy was safe and feasible for the treatment of LANSCLC with low incidence of postoperative complications and mortality. Unfortunately, this study did not compare the surgical and survival outcomes of VATS with those of thoracotomy.

Another study reported by Bernard J. Park et al. [12] compared minimally invasive lobectomy (VATS and robotic) with open lobectomy and concluded that minimally invasive surgery possessed good feasibility, good safety and an acceptable survival time in appropriately selected patients with LANSCLC after neoadjuvant chemotherapy. However, this study mainly focused on lung adenocarcinoma and lobectomy. Meanwhile, the age between two groups had statistical difference, which might cause potential bias in the conclusion.

In this study, we explored whether VATS was suitable to be applied in locally advanced LSCC staged by AJCC 8 staging system or not. We observed similar operative time and blood loss between VATS and thoracotomy, but VATS had advantages in postoperative pain and chest drainage. Interestingly, duration of chest drainage was similar in two groups, but the length of postoperative hospital stay was seemed to be shorter in VATS group although the difference was not statistically

| Table 3 Perioperative data in the thoracotomy and VATS group |
|-------------------------------------------------------------|
| Variables | Thoracotomy (N = 69) | VATS (N = 14) | P value | Cohen's d value | Statistical power |
| Surgical procedure | | | | | |
| Sublobar resection | 1 (1.5%) | 2 (14.3%) | 0.078 | | |
| Lobectomy | 39 (58.2%) | 8 (57.1%) | | | |
| Bilobectomy | 6 (9.0%) | 3 (21.4%) | | | |
| Sleeve lobectomy | 9 (13.4%) | 1 (7.1%) | | | |
| Double sleeve lobectomy | 2 (3.0%) | 0 (0) | | | |
| Pneumonectomy | 10 (14.9%) | 0 (0) | | | |
| Surgical margin | | | 0.760 | | |
| R0 | 59 (88.1%) | 13 (92.9%) | | | |
| R1 | 7 (10.4%) | 1 (7.1%) | | | |
| R2 | 1 (1.5%) | 0 (0) | | | |
| Number of resected LNs | 20 (2–57) | 16 (1–28) | 0.011 | 0.838 | 80.4% |
| Number of resected LN stations | 7 (2–12) | 7 (1–10) | 0.085 | | |
| Nodal upstaging | 13 (19.4%) | 4 (28.6%) | 0.685 | | |
| Operation time (minutes) | 146 (87–410) | 145 (73–364) | 0.411 | | |
| Blood loss (ml) | 100 (20–400) | 83 (10–500) | 0.819 | | |
| Numerical pain rating scale | 2 (1–7) | 2 (1–3) | 0.005 | 0.676 | 62.2% |
| Chest drainage (ml) | 1035 (150–5850) | 550 (30–2100) | 0.019 | 0.835 | 80.1% |
| Duration of chest drainage (days) | 5 (2–20) | 4 (2–15) | 0.285 | | |
| Complications | 20 (29.9%) | 3 (21.4%) | 0.729 | | |
| Gradel | 9 (13.4%) | 1 (7.1%) | | | |
| Gradell | 9 (13.4%) | 2 (14.3%) | | | |
| Gradelll | 2 (3.0%) | 0 (0) | | | |
| Postoperative hospital stay (days) | 7 (4–21) | 6 (4–16) | 0.066 | | |
| Mortality within 30 days | 0 (0) | 0 (0) | / | | |
| Delay of adjuvant therapy (days) | 40 (21–127) | 36 (23–57) | 0.353 | | |
| Protocol of Adjuvant therapy | | | 0.275 | | |
| Chemotherapy | 36 (53.7%) | 10 (71.4%) | | | |
| Radiotherapy | 6 (9.0%) | 0 (0) | | | |
| Chemoradiotherapy | 16 (23.9%) | 4 (28.6%) | | | |
| Unknown | 9 (13.4%) | 0 (0) | | | |

Values are N (percentage) or median (range)

LN lymph node
significant. The rate and the severity of complications were also comparable. These results suggested that VATS played a positive role in enhanced recovery after surgery (ERAS) in locally advanced LSCC with equivalent survival to thoracotomy.

Systematic lymph node resection is an important part of surgical treatment for LANSCLC. It is a controversial problem about the quality of nodal assessment provided by VATS when compared to thoracotomy and its impact on long-term survival. Some publications indicated more lymph nodes were resected and a higher nodal upstaging rate was found in open surgery [29], while other studies suggested no correlation between the surgical approach and the number of lymph nodes resected [30]. In this study, we thoroughly analyzed the quality of lymph node resection between VATS and thoracotomy after neoadjuvant chemotherapy. Although the number of resected lymph node in VATS group was less than that in thoracotomy group, the number of resected stations and the rate of nodal upstaging were both similar in two groups.
It suggested that a radical lymph node dissection could be achieved by VATS following neoadjuvant chemotherapy. It was worthwhile to note that the rate of negative margin of VATS was equivalent to that of thoracotomy. However, there are some limits in this study. First, it is the retrospective study that has unavoidable selected bias, so further prospective evidence is warranted to verify the validity of our findings. Second, this study included some patients restaged IIIB disease because of the difference between the seventh AJCC staging system and the eighth in the T stage, but most patients were diagnosed as stage IIIA or IIIB. Lastly, the sample is relatively small in this study, although the statistical power analysis was further conducted when the differences between the two groups were statistically significant.

Conclusions
This study suggested that in selected patients with locally advanced LSCC VATS following neoadjuvant chemotherapy played a positive role in ERAS and associated similar oncological and survival outcome with thoracotomy.

Abbreviations
LSCC: Lung squamous cell carcinoma; LA: Lung adenocarcinoma; NSCLC: Non-small cell lung cancer; LANSCLC: Locally advanced non-small cell lung cancer; VATS: Video-assisted thoracic surgery; DFS: Disease-free survival; OS: Overall survival; AJCC: The eighth American Joint Committee on Cancer; LN: Lymph node; BMI: Body mass index; cCR: Clinical complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ERAS: Enhanced recovery after surgery; COPD: Chronic obstructive pulmonary disease

Acknowledgements
Not applicable.

Funding
This study was funded by Major science and technology projects of Zhejiang province (2014C03032), Key research project of traditional Chinese medicine science and technology plan in Zhejiang Province (2015Z2007) and National Key R&D Program of China (2017YFC0133500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
JH and LF contributed to the conception and design of the work. LF and LW contributed to data acquisition, statistical analysis and interpretation of the data. JH, LW and YW contributed to the revision of the manuscript. All authors have approved the final draft of the manuscript and there are no conflicts of interest.

Ethics approval and consent to participate
The study protocol was approved by the Institutional Review Board of the First Affiliated Hospital of Zhejiang University, School of Medicine.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012[J]. CA Cancer J Clin. 2015;65(2):87–108.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adelj AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J]. Mayo Clin Proc. 2008;83(5):584–94.
3. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RJ, Jones DR, McKenna RJ, Landreneau RJ, Rusch VW, Putnam JB Jr. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial [J]. J Thorac Cardiovasc Surg. 2011;141(3):662–70.
4. van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC [J]. J Thorac Oncol. 2015;10(5):826–31.
5. Berghmans T, Paemans M, Sculeri JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables [J]. Ther Adv Med Oncol. 2013;5(3):127–38.
6. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J]. Lancet. 2014;383(9928):1561–71.
7. Pless M, Stupp R, Nass H-B, Stahel RA, Weder W, Thierstein S, Gerard M-A. Induction chemoradiation in stage II/III A non-small-cell lung cancer: a phase 3 randomised trial [J]. Lancet. 2015;386(9998):1049–56.
8. Hanna WC, de Valence M, Atenafu EG, Cypel M, Waddell TK, Yaszufuku K, Pierre A, De Perrot M, Keshavjee S, Darling GE. Is video-assisted lobectomy for non-small-cell lung cancer oncologically equivalent to open lobectomy? [J]. Eur J Cardiothorac Surg. 2013;43(6):1121–5.
9. Klappper J, D’Amico TA. VATS versus open surgery for lung cancer resection: moving toward a minimally invasive approach [J]. J Natl Compr Canc Netw. 2015;13(2):162–4.
10. Zhou S, Pei G, Han Y, Yu D, Song X, Li Y, Xiao N, Liu S, Liu Z, Xu S. Sleeve lobectomy by video-assisted thoracic surgery versus thoracotomy for non-small cell lung cancer [J]. J Cardiothorac Surg. 2015;10:116.
11. Gonzalez-Rivas D, Yang Y, Stupnik T, Sekhniaidze D, Fernandez R, Velasco C, Zhu Y, Jiang G. Uniportal video-assisted thoracoscopic surgery for non-small cell lung cancer: a systematic review [J]. J Thorac Surg. 2016;15(Suppl 4):S406–13.
12. Huang J, Xu X, Chen H, Yin W, Shao W, Xiong X, He J. Feasibility of complete video-assisted thorascoscopic surgery following neoadjuvant therapy for locally advanced non-small cell lung cancer [J]. J Thorac Dis. 2016;8(Suppl 4):S406–13.
13. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American joint committee on Cancer eighth edition [J]. Lung Cancer. 2016;98:45(2):228–47.
14. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, Jiao Y. Obesity and incidence of lung cancer: a meta-analysis [J]. Int J Cancer. 2013;132(5):1162–9.
15. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an eastern cooperative oncology group study [J]. J Clin Oncol. 1986;4(5):702–9.
18. Akamine T, Toyokawa G, Matsuura T, Kozuma Y, Haratake N, Takamori S, Katsura M, Takada K, Shoji F, Okamoto T, Maehara Y. Significance of the preoperative CONUT score in predicting postoperative disease-free and overall survival in patients with lung adenocarcinoma with obstructive lung disease [J]. Anticancer Res. 2017;37(5):2735–42.

19. Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: a ratio measure? [J]. Pain Pract. 2003;3(4):310–6.

20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey [J]. Ann Surg. 2004;240(2):205–13.

21. Koletis EN, Pronkis E, Apostolakis E, Chatzimichalis A, Dougenis D. Surgery after induction chemoradiotherapy for non small cell lung cancer: when and why [J]. J. buon. 2007;12(4):453–61.

22. Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsusan-Schnitz SF, Minmanoff RO, Ris HB, Pless M. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIb non-small-cell lung cancer: a multicentre phase II trial [J]. Lancet Oncol. 2009;10(8):785–93.

23. Koletsis EN, Proakis C, Apostolakis E, Chatzimichalis A, Dougenis D. Surgery after induction chemoradiotherapy for non small cell lung cancer: when and why [J]. J. buon. 2007;12(4):453–61.

24. Li S, Fan J, Liu J, Zhou J, Ren Y, Shen C, Che G. Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients [J]. Jpn J Clin Oncol. 2016;46(6):534–46.

25. Sher DJ, Fidler MJ, Liptay MJ, Koshy M. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer [J]. Lung Cancer. 2015;88(3):267–74.

26. Brouchet L, Bauvin E, Marcheix B, Bigay-Garne L, Renaud C, Berjaud J, Falcone PE, Verissac N, Ren J, Jablons D, Mazieres J, Dahan M. Impact of induction treatment on postoperative complications in the treatment of non-small cell lung cancer [J]. J Thorac Oncol. 2007;2(7):626–31.

27. Glover J, Veluz-Cubian FO, Toosi K, Ng E, Moodie CC, Garrett JR, Fontaine JP, Toloza EM. Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer [J]. J Thorac Dis. 2016;8(8):2165–74.

28. Gao SJ, Conso CD, Wang EH, Blasberg JD, Deterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of surgery after neoadjuvant Chemoradiation in locally advanced non-small cell lung Cancer [J]. J Thorac Oncol. 2017;12(2):314–22.

29. Merritt RE, Hoang CD, Shraga JB. Lymph node evaluation achieved by open lobectomy compared with thoracoscopic lobectomy for N0 lung cancer [J]. Ann Thorac Surg. 2013;95(4):1171–2.

30. Zhong C, Yao F, Zhao H. Clinical outcomes of thoracoscopic lobectomy for patients with clinical N0 and pathologic N2 non-small cell lung cancer [J]. Ann Thorac Surg. 2013;95(3):987–92.